Omega 3 s and Cardiovascular Disease: High vs. Low Dose? Terry A. Jacobson M.D., F.N.L.A. Emory University Atlanta, GA
|
|
- Suzan Bailey
- 6 years ago
- Views:
Transcription
1 Omega 3 s and Cardiovascular Disease: High vs. Low Dose? Terry A. Jacobson M.D., F.N.L.A. Emory University Atlanta, GA
2 Structure of Omega-3 and Omega-6 Fatty Acids Omega-6 fatty acids CH 3 Omega-3 fatty acids Plant derived C18:2n-6 Linoleic acid COOEt COOH CH 3 C18:3n-3 -Linolenic acid COOH CH 3 Marine derived C20:4n-3 Arachidonic acid COOH CH 3 C20:5n-3 COOH Eicosapentaenoic acid CH 3 C22:5n-6 COOH Docosapentaenoic acid CH 3 C22:6n-3 COOH Docosahexaenoic acid Din JN et al. BMJ. 2004;328: Reprinted with permission from BMJ Publishing Group.
3 Major Dietary Sources of EPA and DHA U.S. Department of Agriculture, USDA National Nutrient Database for Standard Reference. EPA mg/100g DHA mg/100g EPA and DHA mg Anchovy Herring, Atlantic 909 1,105 2,014 Salmon, farmed 862 1,104 1,966 Salmon, wild 411 1,429 1,840 Mackerel, Atlantic ,203 Bluefish Sardines, Atlantic Trout Golden bass (tilefish) Swordfish Tuna, white (albacore) Mussels Oysters, wild King Mackerel Tuna, light (skipjack) Snapper Flounder and sole Clams Grouper Halibut Lobster Scallops Blue Crab Cod, Pacific Shrimp Catfish, farmed
4 Available Forms of Omega-3 Fatty Acids for Supplement and Pharmaceutical use Harris WS and Jacobson TA. In Clinical Lipidology: A Companion to Braunwald s Heart Disease: Expert Consult (2 nd edition) Editor Christie M. Ballantyne (2014, in press)
5 ECLIPSE STUDY: Epanova Compared to Lovaza in a Pharmacokinetic Single-dose Evaluation Kataoka Y et al. Future Cardiol. 2013;9:
6 AHA Recommendations for Omega-3 FA Intake Population Patients without documented CHD Patients with documented CHD Patients needing triglyceride lowering Recommendation Eat a variety of (preferably oily) fish at least twice a week. Include oils and foods rich in -linolenic acid (flaxseed, canola, and soybean oils; flaxseeds; and walnuts) Consume ~1 g of EPA+DHA per day, preferably from oily fish. EPA+DHA supplements could be considered in consultation with the physician 2 4 grams of EPA+DHA per day provided as capsules under a physician s care Kris-Etherton PM et al. Circulation 2002;106:
7 What Percent of Whale Blubber in Maui is EPA & DHA?
8 n-3 Fatty Acid Randomized Controlled Trials Assessing Cardiovascular Outcomes Trial, Year Population Interventions Compared DART 1989 GISSI-P ,033 men with recent MI (mean 41 days) 11,324 men with recent MI ( 3 mo) 2 servings/wk fatty fish (or fish oil capsules) vs other dietary advice Usual care plus 882 mg/day EPA+DHA, vitamin E, both or neither Duration years Lipid Effects Endpoints RR (95% CI) 2 No change in TC IHD events Total deaths 3.5 No change in TC, LDL-C or HDL- C; 5% decrease in TG Major CV events Non-fatal events Cardiac deaths Sudden deaths 0.84 ( ) 0.71 ( ) 0.90 ( ) 0.98 ( ) 0.78 ( ) 0.74 ( ) JELIS ,645 patients with total cholesterol 6.5 mmol/l (with and without CHD history) 1.8 g/day EPA vs usual care 4.6 No change in TC, LDL-C or HDL- C; 6% decrease in TG Coronary events Non-fatal events Coronary deaths Sudden deaths 0.81 ( ) 0.81 ( ) 0.94 ( ) 1.06 ( ) GISSI-HF patients with heart failure 840 mg/day EPA+DHA vs placebo (not defined) 3.9 No change in TC, LDL-C or HDL- C; 5% decrease in TG Total death Death or hospitalization for CVD 0.91 ( ) 0.94 ( ) DART = Diet and Reinfarction Trial; GISSI-P = Gruppo Italiano per lo Studio della Soppravvivenza nel Infarto Miocardico Prevenzione; JELIS = Japan EPA Lipid Intervention Study; GISSI-HF = Gruppo Italiano per lo Studio della Soppravvivenza nel Infarto Miocardico Heart Failure Harris WS and Jacobson TA. In Clinical Lipidology: A Companion to Braunwald s Heart Disease: Expert Consult (2 nd edition) Editor Christie M. Ballantyne (2014, in press)
9 Recent n-3 Fatty Acid Randomized Controlled Trials Assessing Cardiovascular Outcomes RCT = randomized control trial; MI = myocardial infarction; IHD = ischemic heart disease; CV = cardiovascular; CHD = coronary heart disease; IGT Iimpaired glucose tolerance; IFG = impaired fasting glucose; NR = not reported; TC = total cholesterol; HDL = high density lipoprotein; LDL = low density lipoprotein; TG = triglycerides; SU.FOL.OM3 = Supplementation en Folates et Omega-3; ORIGIN = Outcome Reduction with Initial Glargine Intervention. Harris WS and Jacobson TA. In Clinical Lipidology: A Companion to Braunwald s Heart Disease: Expert Consult (2 nd edition) Editor Christie M. Ballantyne (2014, in press)
10 Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events: A Systematic Review and Meta-analysis (2012) Error bars indicate 95% CIs; PUFAs, polyunsaturated fatty acids; RR, relative risk. Rizos EC et al. JAMA. 2012;308(10):
11 Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events: A Systematic Review and Meta-analysis (2012) Error bars indicate 95% CIs; PUFAs, polyunsaturated fatty acids; RR, relative risk. Rizos EC JAMA. 2012;308(10)
12 Are n-3 Fatty Acids Still Cardioprotective? Observational Studies Mechanism of Action Randomized Controlled Trials Meta-Analysis n-3 Dose: High vs. Low Design of Future Outcome Trials
13 Mozaffarian, D. et al. JAMA 2006;296:
14 Are n-3 Fatty Acids Still Cardioprotective? Mechanism of Action 1.Benefit of omega 3 s probably unrelated to changes in lipids - no Δ in lipids in JELIS - no Δ in lipids in GISSI-Prevenzione - no Δ in lipids in GISSI-Heart Failure 2. Many non-lipid mechanisms of action 3. The different cardiovascular benefits of omega 3 s are dependent on their doses, with antiarrythmic effects at low doses, and lipid lowering effects at higher doses
15 Are n-3 Fatty Acids Still Cardioprotective? Lipid Changes: 1. No evidence reducing TG s reduces CHD or CVD events 2. High dose omega 3 s (> 2-4 grams/day) are required to change lipid levels 3. No RCT evidence yet that lipid lowering doses of omega 3 s (>2-4g/day) reduce CHD risk or have better outcomes than low doses of omega 3 s (1-2g/day).
16 Are n-3 Fatty Acids Still Cardioprotective? Observational Studies Mechanism of Action Randomized Controlled Trials Meta-Analysis n-3 Dose: High vs. Low Design of Future Outcome Trials
17 The GISSI-Prevenzione Trial Post-MI Total Number of Patients 11,324 Omega 3 5,666 1 capsule/day Control 5,658 Vitamin E 2,836 Control 2,830 Vitamin E 2,830 Control 2,828 Hard endpoints. Duration: 3.5 years (start 1993) 172 centers in Italy involved, managed by the Mario Negri Institute
18 Probability GISSI-Prevenzione Trial: Early Effect on All-Cause Mortality GISSI-Prevenzione Trial: Early Effect on All-Cause Mortality Omacor (95% CI ) P = Control Omega Days Marchioli R et al. Circulation 2002;105: Control Omega 3 RR P-Value All-Cause Mortality 10.6% 8.4% 21% Sudden Death 3.3% 1.8% 44% R Marchioli, et al., Circulation 2002; 105: Days 18
19 CONFIDENTIAL 2006
20 n > 18,000 (Japan) All administered statins 1 o & 2 o prevention 5 yr f/u 1,800 mg EPA/day Mean TG= 150 mg/dl Yokoyama M et al. Lancet 2007;370:215
21 Cohort Profile 18,645 Random allocation 14,981 Primary prevention 3,664 Secondary prevention 7,478 Control group 7,503 EPA group 1,841 Control group 1,823 EPA group
22 Event rate (%) Change from baseline (%) Addition of Eicosapentaenoic Acid (EPA) to Statin Therapy in Japanese Patients Major CHD Events * Lipid Effects % Reduction P= Statin (n=9319) Statin + EPA 1.8 g (n=9326) P< Statin -40 LDL-C TC TG *Sudden cardiac death, fatal and non-fatal MI, unstable angina, angioplasty, stenting, or CABG. CHD=coronary heart disease; LDL-C=low-density lipoprotein cholesterol; TC=total cholesterol. Yokoyama M et al. Lancet. 2007;369:
23 Cumulative Incidence of Major Coronary Events (%) Kaplan-Meier Estimates of Major Coronary Events 4-19% 3 Control 2 EPA No at Risk Control EPA 1 Hazard ratio: 0.81 ( ) P= Years 9,319 8,931 8,671 8,433 8,192 7,958 9,326 8,929 8,658 8,389 8,153 7,924
24 Major Coronary Events Incidence No. of events (%) Control N=9,319 EPA N=9,326 P Value Hazard Ratio (95% CI) Major coronary events 324 (3.5) 262 (2.8) ( ) Sudden cardiac death 17 (0.2) 18 (0.2) ( ) Fatal MI 14 (0.2) 11 (0.1) ( ) Nonfatal MI 83 (0.9) 62 (0.7) ( ) Unstable angina 193 (2.1) 147 (1.6) ( ) CABG or PTCA 222 (2.4) 191 (2.1) ( )
25 The JELIS Study: Conclusions The addition of eicosapentaenoic acid (EPA) to low-dose statin therapy significantly reduced the incidence of major coronary events, largely driven by a reduction in unstable angina, when compared with patients taking statins alone The benefits in secondary prevention were greater than those in primary prevention
26 Recent n-3 Fatty Acid Randomized Controlled Trials Assessing Cardiovascular Outcomes RCT = randomized control trial; MI = myocardial infarction; IHD = ischemic heart disease; CV = cardiovascular; CHD = coronary heart disease; IGT Iimpaired glucose tolerance; IFG = impaired fasting glucose; NR = not reported; TC = total cholesterol; HDL = high density lipoprotein; LDL = low density lipoprotein; TG = triglycerides; SU.FOL.OM3 = Supplementation en Folates et Omega-3; ORIGIN = Outcome Reduction with Initial Glargine Intervention. Harris WS and Jacobson TA. In Clinical Lipidology: A Companion to Braunwald s Heart Disease: Expert Consult (2 nd edition) Editor Christie M. Ballantyne (2014, in press)
27
28
29 Are Omega s Still Cardioprotective?: Why Current Trials Failed n-3 PUFA do not reduce CVD events n-3 PUFA have little benefit on top of aggressive medical treatments including statins, antiplatelet agents, etc. n-3 PUFA trials have been inadequately powered to detect a clinically meaningful effect on CHD deaths, the endpoint most likely to be effected based on both epidemiological and clinical trial data n-3 PUFA background therapy has increased due to increased fish consumption and greater use of fish oil supplements n-3 PUFA doses in clinical trials, have been too low ( g EPA and DHA) to effect long term plaque stabilization (2-4gms) n-3 PUFA have a limited benefit on CHD deaths after a threshold intake has been reached of 250 mg/day.
30 Are Omega s Still Cardioprotective?: Why Current Trials Failed n-3 PUFA do not reduce CVD events n-3 PUFA have little benefit on top of aggressive medical treatments including statins, antiplatelet agents, etc. n-3 PUFA trials have been inadequately powered to detect a clinically meaningful effect on CHD deaths, the endpoint most likely to be effected based on both epidemiological and clinical trial data n-3 PUFA background therapy has increased due to increased fish consumption and greater use of fish oil supplements n-3 PUFA doses in clinical trials, have been too low ( g EPA and DHA) to effect long term plaque stabilization (2-4gms) n-3 PUFA have a limited benefit on CHD deaths after a threshold intake has been reached of 250 mg/day.
31 Are Omega s Still Cardioprotective?: Why Current Trials Failed n-3 PUFA do not reduce CVD events n-3 PUFA have little benefit on top of aggressive medical treatments including statins, antiplatelet agents, etc. n-3 PUFA trials have been inadequately powered to detect a clinically meaningful effect on CHD deaths, the endpoint most likely to be effected based on both epidemiological and clinical trial data n-3 PUFA background therapy has increased due to increased fish consumption and greater use of fish oil supplements n-3 PUFA doses in clinical trials, have been too low ( g EPA and DHA) to effect long term plaque stabilization (2-4gms) n-3 PUFA have a limited benefit on CHD deaths after a threshold intake has been reached of 250 mg/day.
32 Are Omega s Still Cardioprotective?: Why Current Trials Failed Populations consuming little or no fish intake have not been studied n-3 PUFA therapy has not been tested at doses required to significantly effect lipoproteins (triglycerides, non-hdl-c, apo B, or apo C-III) n-3 PUFA therapy has not been tested in individuals with high triglycerides or with other related lipid abnormalities (low HDL-C) despite a suggestion of potential large benefit in post-hoc analysis of randomized trials
33 Are n-3 Fatty Acids Still Cardioprotective? Observational Studies Mechanism of Action Randomized Controlled Trials Meta-Analysis n-3 Dose: High vs. Low Design of Future Outcome Trials
34 JELIS: Change from Baseline in Omega 3 Fatty Acid Levels (ug/ml) Itakura, H et al. J. Atheroscler. Thromb. 2011, 18 :
35 JELIS: Relationship between On-Treatment EPA Concentration and Adjusted Major Coronary Events Itakura, H et al. J. Atheroscler. Thromb. 2011, 18 :
36 JELIS:! % of Patients Achieving EPA 150ug/ml: Control Group (10%) vs EPA Group (61%) Itakura, H et al. J. Atheroscler. Thromb. 2011, 18 :
37 Are Omega s Still Cardioprotective?: Why Current Trials Failed n-3 PUFA do not reduce CVD events n-3 PUFA have little benefit on top of aggressive medical treatments including statins, antiplatelet agents, etc. n-3 PUFA trials have been inadequately powered to detect a clinically meaningful effect on CHD deaths, the endpoint most likely to be effected based on both epidemiological and clinical trial data n-3 PUFA background therapy has increased due to increased fish consumption and greater use of fish oil supplements n-3 PUFA doses in clinical trials, have been too low ( g EPA and DHA) to effect long term plaque stabilization (2-4 gms) n-3 PUFA have a limited benefit on CHD deaths after a threshold intake has been reached of 250 mg/day.
38 Definition of Insanity Insanity is doing the same thing over and over again and expecting different results.
39 Are n-3 Fatty Acids Still Cardioprotective? Observational Studies Mechanism of Action Randomized Controlled Trials Meta-Analysis n-3 Dose: High vs. Low Design of Future Outcome Trials
40 Summary of Key OMEGA-3 Outcomes Studies GISSI study JELIS study REDUCE-IT Population Italian Japanese International N 11,324 18,645 ~8,000 Male: Female 85% male 31% male - Risk profile OM-3 formulation & dosage Recent MI ( 3 mths; median 16 days) Omacor 1 g/day (EPA/DHA) 40 80% 1 o prevention; TC 6.5 mmol/l; excluded MI 6 months Epadel 1.8 g/day (pure EPA) Established vascular dx Diabetes (+) TG mg/dl EPA-E 4 g/day Follow-up 3.5 years 4.6 years 4-5 years Statin use Endpoint Result LDL-C 4.7% baseline/45.5% at end Death, non-fatal MI, stroke RRR 10%/15% (2- or 4- way analysis) Increased ~3% > control groups All on Low Dose Background Statins MACE RRR 19% No Difference Between both groups All on Background Statins (LDL-C goal) MACE Powered for 15% RRR SCD RR = 0.74/0.55 RR=
41 Summary: Are n-3 Fatty Acids Still Cardioprotective? Although recent n-3 fatty acid intervention studies have not demonstrated a beneficial effect on total cardiovascular outcomes, the totality of evidence suggests that CHD mortality is reduced at a low doses Properly designed clinical trials are needed assessing populations with low background n-3 fatty acid intake and using higher n-3 fatty acid doses (2-4gms) to either affect lipids or other mechanisms involved in plaque stabilization The risk-benefit ratio of n-3 fatty acids for reducing risk for cardiovascular disease still remains favorable in the right patient at the right dose.
Omega-3 Fatty Acids. Alison L. Bailey MD, FACC Erlanger Heart and Lung Institute/University of Tennessee COM
Omega-3 Fatty Acids Alison L. Bailey MD, FACC Erlanger Heart and Lung Institute/University of Tennessee COM Chattanooga @a_l_bailey Disclosures None Objectives Describe omega-3 fatty acids Review the historic
More informationThe health benefits of shellfish: What should we be promoting? Professor Bruce Griffin Nutrition Division Faculty of Health & Medical Sciences
The health benefits of shellfish: What should we be promoting? Professor Bruce Griffin Nutrition Division Faculty of Health & Medical Sciences What should we be promoting? Define health benefits in terms
More informationThe Effect of Fish Oil On Cardiovascular Mortality Resident Pharmacotherapy Rounds
The Effect of Fish Oil On Cardiovascular Mortality Resident Pharmacotherapy Rounds Kerry-Ann Fuller, PharmD PGY1 Resident UT/HEB Community Pharmacy Residency Preceptor: James Weems, RPh Residency Director:
More informationTable 1: Dietary Sources of Omega-3 and Omega-3 Fatty Acids. Fatty Acid. Food Sources. (i) Omega-6 Types. LA, linoleic acid (18:2 n-6)
As for saturated and monounsaturated fatty acids, the omega-6 and omega-3 polyunsaturated fatty acids (PUFA) are chemically linked to fat structures known as triglycerides in the various foods and oils
More informationHeart Healthy IET. Talia den Dulk Clinical Dietitian
Heart Healthy IET Talia den Dulk Clinical Dietitian Heart facts Coronary heart disease is the second biggest killer of South Africans after HIV/Aids Each day 33 South Africans die from a heart attack,
More informationName of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor
Name of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor Policy #: 239 Latest Review Date: July 2010 Category: Laboratory Policy Grade: Active
More informationFacts on Fats. Ronald P. Mensink
Facts on Fats Ronald P. Mensink Department of Human Biology NUTRIM, School for Nutrition, Toxicology and Metabolism Maastricht University Maastricht The Netherlands Outline of the Presentation Saturated
More informationLipid & Fat: Overview
Lipid & Fat: Overview What is a lipid? Triglycerides, Phospholipids and Sterols Triglycerides = Fat Saturated & unsaturated Essential fatty acids ü Omega 3 & Omega 6 Trans fat Why do you need fat? How
More informationTara Dall, MD Advanced Lipidology Diplomate American Board Clinical Lipidology
Role of Omega-3 Fatty Acids in Cardiovascular Disease Prevention Tara Dall, MD Advanced Lipidology Diplomate American Board Clinical Lipidology www.advlip.com 3 Types of Fat 1 Fat effect on cholesterol
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationFuture directions for nutritional and therapeutic research in omega-3 3 lipids
Future directions for nutritional and therapeutic research in omega-3 3 lipids Philip Calder Professor of Nutritional Immunology University of Southampton Aim To review dietary sources and intakes of long
More informationFish Oils and Stroke/Blood Coagulation
Fish Oils and Stroke/Blood Coagulation Summaries of the latest research concerning fish oils and stroke and blood coagulation Review supports benefits of omega-3 fatty acids for prevention of heart disease
More informationNot Hard Choices. By Dato Dr. Rajen M. 27 October 2018
Make Choices Not Hard Choices By Dato Dr. Rajen M. 27 October 2018 Key Facts of Cardiovascular Disease 1. What is the burden of cardiovascular disease in Malaysia? 2. What causes cardiovascular disease?
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationFish oil and cardiovascular science supporting global regulatory efforts
Fish oil and cardiovascular science supporting global regulatory efforts Dr Harry Rice Your essential event for networking and information Fish Oil and Cardiovascular Science Supporting Global Regulatory
More informationFISH. College of Applied Medical Sciences Department of Community Health Sciences Clinical Nutrition Functional Foods CHS 457 Level 9
College of Applied Medical Sciences Department of Community Health Sciences Clinical Nutrition Functional Foods CHS 457 Level 9 FISH Presented By: Nada Abdullah Al-Akeil Supervised By: Mrs.Madawi Al-Dhwayan
More informationLipid & Fat: Overview
Lipid & Fat: Overview What is a lipid? Triglycerides, Phospholipids and Sterols Triglycerides = Fat Saturated & unsaturated Essential fatty acids ü Omega 3 & Omega 6 Trans fat Why do you need fat? How
More informationFish Intake, Marine Omega-3 Fatty Acids, and Mortality in a Cohort of Postmenopausal Women
American Journal of Epidemiology Copyright 2004 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 160, No. 10 Printed in U.S.A. DOI: 10.1093/aje/kwh307 Fish Intake, Marine
More informationFish Oils and Diabetes
Fish Oils and Diabetes Summaries of the latest research concerning fish oils and diabetes Fish oils benefit women with diabetes BOSTON, MASSACHUSETTS. Several studies have found a clear inverse association
More informationThe ERA JUMP Study: Reevaluating the Omega- 3 Index
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/the-era-jump-study-reevaluating-the-omega-3-
More informationNew evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
More informationOmega-3 requirements - length matters!
Omega-3 requirements - length matters! http://www.rejuvenal.info/ images/terminology/omega3.png Professor Peter Howe Nutritional Physiology Research Centre University of South Australia Food Industry Forum
More informationComment from Professor Holub:
The Medical Officer and associates for Toronto Public Health have just released a major Technical Report entitled 'Fish Consumption: Benefits and Risks for Women in Childbearing Years and Young Children'.
More informationFatty acids and cardiovascular health: current evidence and next steps
Fatty acids and cardiovascular health: current evidence and next steps Emanuele Di Angelantonio, MD, PhD Department of Public Health and Primary Care NICE guidelines on fatty acids Eliminate the use of
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationEditorial. New evidence that omega-3 fatty acids have a role in primary prevention. of coronary heart disease. Philip C. Calder
Editorial New evidence that omega-3 fatty acids have a role in primary prevention of coronary heart disease Philip C. Calder Faculty of Medicine, University of Southampton, Southampton, United Kingdom
More informationSupplementary Online Content
Supplementary Online Content Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals.
More informationThe Cost Effectiveness of Omacor post-myocardial infarction in the Irish Healthcare Setting
The Cost Effectiveness of Omacor post-myocardial infarction in the Irish Healthcare Setting April 2013 1. Omacor is a concentrated preparation of omega-3-acid ethyl esters that contains 46% eicosapentaenoic
More informationDietary Reference Values: a Tool for Public Health
HOGE GEZONDHEISRAAD Dietary Reference Values: a Tool for Public Health CONSEIL SUPERIEUR DE LA SANTE Belgian Dietary Reference Values for Energy and Macronutrients: FATS G. De Backer Brussels, February
More informationOmega 3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review Executive Summary
Evidence Report/Technology Assessment Number 223 Omega 3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review Executive Summary Introduction Since the first ecological study published in
More informationA classic case of why conventional lipid testing is not enough.
ILLUSTRATIVE EXAMPLE #1 PRIMARY PREVENTION A classic case of why conventional lipid testing is not enough. A 59-year-old woman presents with recent chest discomfort. She has a family history of premature
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationRole of n 3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease 1 3
Role of n 3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease 1 3 Terry A Jacobson ABSTRACT n 3 Fatty acids (FAs) when used in doses of 3 4 g/d eicosapentaenoic acid and docosahexaenoic
More informationRecent Advances & Emerging Data in the Treatment of Hypertriglyceridemia. Michael Miller, MD, FACC, FAHA, FNLA
Recent Advances & Emerging Data in the Treatment of Hypertriglyceridemia Michael Miller, MD, FACC, FAHA, FNLA Professor of Medicine, Epidemiology & Public Health University of Maryland School of Medicine
More informationIngredients in Clinical Practice. Zhaoping Li, M.D., Ph.D. Professor of Medicine David Geffen School of Medicine UCLA
Ingredients in Clinical Practice Zhaoping Li, M.D., Ph.D. Professor of Medicine David Geffen School of Medicine UCLA In the Beginning.. There were Plants and Herbs Soil Then The Plants Made Oxygen Using
More informationSeafood for Health Information for Healthcare Providers Part 1
Seafood for Health Information for Healthcare Providers Part 1 Dr. Michael Morrissey, Dr. Rosalee Hellberg, Laura Geise of Oregon State University Dr. Lori Pivarnik of the University of Rhode Island Doris
More informationFLAXSEED Health Benefits and Functionality. Kelley C. Fitzpatrick Director of Health FLAX COUNCIL OF CANADA
FLAXSEED Health Benefits and Functionality Kelley C. Fitzpatrick Director of Health FLAX COUNCIL OF CANADA Consumers are interested in Positive Nutrition The trend is no longer just to remove bad ingredients
More informationDyerberg Discovery. Greenland Eskimos have low rates of heart disease while their diet is high in saturated fat and cholesterol. That s strange. Why?
Omega-3 Dyerberg Discovery Greenland Eskimos have low rates of heart disease while their diet is high in saturated fat and cholesterol. That s strange. Why? They eat a large amount of omega-3 (10g /d)
More informationDietary Cholesterol in Cold Water Prawns: Implications for Cardiovascular Disease Risk
Dietary Cholesterol in Cold Water Prawns: Implications for Cardiovascular Disease Risk Professor Bruce Griffin Department of Nutritional Sciences Faculty of Health & Medical Sciences Coronary Heart Disease
More informationMacrovascular Management. What s next beyond standard treatment?
Macrovascular Management What s next beyond standard treatment? Are Lifestyle Modifications Still Relevant in Diabetic Patients? Diet Omega-6 and omega-3 fatty acids have been shown to improve CVD risk
More informationThere are three major types of omega-3 fatty acids that are ingested in foods and used by the body:
Long-chain fatty acids (LC-PUFAs: ARA, DHA and EPA) AT A GLANCE Introduction LC-PUFAs or long chain polyunsaturated fatty acids are mainly found in the form of two families of conditionally essential fatty
More informationProspective Natural-History Study of Coronary Atherosclerosis
Introduction Review of literature from April 2010 to present Concentrated on clinical studies Categories: Atherosclerosis, Lipids, Diabetes and CVD Risk Medical Therapy Statins really could there be anything
More informationHealth effects of consuming 2 portions per week of Scottish farmed salmon raised on different feeding regimes. Baukje de Roos
Health effects of consuming 2 portions per week of Scottish farmed salmon raised on different feeding regimes Baukje de Roos Sustainable sources of fish as food PROGRAMME Aquaculture has the potential
More informationThe Effects of Lipids on the Body
The Effects of Lipids on the Body Review: 3 general types 1. Triglycerides Major type of fat found in food and in bodies 2. Phospholipids In body: Carry food back and forth across cell membranes In food:
More informationLeaders in Managing Lipids for Improved Cardiovascular Health
Leaders in Managing Lipids for Improved Cardiovascular Health INVESTOR PRESENTATION June 2015 Nasdaq: AMRN Forward-Looking Statement and Disclaimer This presentation contains forward-looking statements,
More informationOUTLINE. The need for fat. What is fat? Types of fats. Dietary sources of the different types of fat
DIETARY FATS OUTLINE The need for fat What is fat? Types of fats Dietary sources of the different types of fat Evidence for cardiovascular health benefit of fish omega-3 and omega-6 fatty acids Possible
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationCholesterol Treatment Update
Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:
More informationTitle :Current & Future Triglyceride Pharmaceuticals
August 23, 2014 Title :Current & Future Triglyceride Pharmaceuticals Harold Bays MD, FTOS, FACC, FACE, FNLA L-MARC Research Center Louisville, KY Disclosures: In the past 12 months, Dr. Harold Bays has
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationCan foods change your health? Good fats and bad fats: what is the evidence? Kay-Tee Khaw. Main categories of fats
Can foods change your health? Good fats and bad fats: what is the evidence? Kay-Tee Khaw UNIVERSITY OF CAMBRIDGE Hong Kong July 6 213 Yerushalmy J Hilleboe HE NY State J Med 1957 Coronary heart disease
More informationDHA/EPA Omega-3 Fatty Acids for Human Health and Chronic Disorders
DHA/EPA Omega-3 Fatty Acids for Human Health and Chronic Disorders Bruce J. Holub, PhD University Professor Emeritus Department of Human Health and Nutritional Sciences University of Guelph, Guelph ON
More informationCardiac patient quality of life. How to eat adequately?
Cardiac patient quality of life How to eat adequately? François Paillard CV Prevention Center CHU Rennes JESFC, Paris, 17/01/2013 Mrs. L. 55 yrs, Coronary artery disease, normal weight, mild hypertension
More informationAquaculture s Role In Nixing the 6, and Eating More Omega-3 s
Aquaculture s Role In Nixing the 6, and Eating More Omega-3 s EPA & DHA most clinically studied ingredient in history Over 2400 on Omega-3s The First 1000 Days of Life Encourage omega-3 intake in women
More informationObjectives 4/4/2013. Healing with Fats and Fatty Acids-- an Integrative approach. Inflammation Nation. A silent attack on the modern human race
Healing with Fats and Fatty Acids-- an Integrative approach Tracy S. Hunter, RPh, MS, PhD Professor Wingate University School of Pharmacy Charlotte Metro-area, NC 1 Objectives Explain the relationship
More informationGiving Good Dietary Advice to Cardiovascular Patients
Giving Good Dietary Advice to Cardiovascular Patients Carmine D Amico, D.O. Learning objectives Introduction Basic principles Grocery shopping Cooking Eating out Snacking Staying active Summary Overview
More informationIs Fin Food Really Good for You, or Is That Just Another Fish Tale? Ed Cox, M.D.
Is Fin Food Really Good for You, or Is That Just Another Fish Tale? Ed Cox, M.D. Confucius taught... Give a man a fish and feed him for a day. Teach a man to fish, and feed him for a lifetime. We now know...
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More information17 MAY SEOUL. IADSA Annual General Meeting Codex Alimentarius / Omega 3
17 MAY SEOUL IADSA Annual General Meeting Codex Alimentarius / Omega 3 Codex Alimentarius CCNSFDU NRV/NCD EPA DHA NRV NCD BASIS FOR NRVs-NCD Need for: What are NRVs-NCD? NRVs-NCD stands for Nutrient Reference
More informationWise Food & Lifestyle Choices For Better Overall Health THE IMPORTANCE OF OMEGA-3 IN YOUR DIET FOOD FOR THOUGHT
Wise Food & Lifestyle Choices For Better Overall Health THE IMPORTANCE OF OMEGA-3 IN YOUR DIET FOOD FOR THOUGHT WHY OMEGA-3 FATS MATTER Did you know omega-3 fats are vital for your health? They play important
More informationn 3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article n 3 Fatty Acids and Cardiovascular Events after Myocardial Infarction Daan Kromhout, M.P.H., Ph.D., Erik J. Giltay, M.D., Ph.D., and
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationEssential Fatty Acids Essential for Good Health SIE
Page 1 of 6 Essential Fatty Acids Essential for Good Health SIE By Yousry Naguib, PhD Essential fatty acids (EFAs) must be obtained through the diet and cannot be synthesized by the human body. EFAs are
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationMARINE Study Results
TM MARINE Study Results Nasdaq: AMRN www.amarincorp.com 1 Forward-Looking Statement This presentation contains forward-looking statements, including those relating to the Company s product development
More informationHeart Health and Fats
ww Heart Health and Fats By Marie Spano, M.S., R.D., C.S.C.S., Contributing Editor Dietary-fat recommendations for heart health are more specific now then ever, breaking down different types of polyunsaturated
More informationAge-related hypertension is there a role for Omega 3 fatty acids in prevention and adjunctive therapy?
Age-related hypertension is there a role for Omega 3 fatty acids in prevention and adjunctive therapy? Dr Rob Winwood CSci FIFST Nutrition Science and Advocacy Manager EMEA for DSM Nutritional Products
More informationPattern of lipid biomarkers and risk of cardiovascular disease
Pattern of lipid biomarkers and risk of cardiovascular disease Robert Clarke Clinical Trial Service Unit University of Oxford 9 January 2017 Biomarkers for dietary fats Blood lipids (LDL, HDL, triglycerides,
More informationThe Mediterranean Diet: The Optimal Diet for Cardiovascular Health
The Mediterranean Diet: The Optimal Diet for Cardiovascular Health Vasanti Malik, ScD Research Scientist Department of Nutrition Harvard School of Public Health Cardiovascular Disease Prevention International
More informationTABLE 1. Association Between Tissue Fatty Acids and Risk of CAD Events, Estimated by Effect Sizes in 25 Studies a All studies No. of Fatty acid g b P
REVIEW OMEGA-3 FATTY ACIDS FOR CARDIOPROTECTION Omega-3 Fatty Acids for Cardioprotection JOHN H. LEE, MD; JAMES H. O KEEFE, MD; CARL J. LAVIE, MD; ROBERTO MARCHIOLI, MD; AND WILLIAM S. HARRIS, PHD The
More informationOverview. The Mediterranean Diet: The Optimal Diet for Cardiovascular Health. No conflicts of interest or disclosures
The Mediterranean Diet: The Optimal Diet for Cardiovascular Health No conflicts of interest or disclosures Vasanti Malik, ScD Research Scientist Department of Nutrition Harvard School of Public Health
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationDepression, omega 3 fatty acid therapy 13
Subject Index Adhesion molecules fish oil effects 12, 13 omega 3 fatty acid desaturase transfection effects on expression in endothelial cells 31 Alzheimer s disease (AD), omega 6 fatty acid/omega 3 fatty
More informationThe Pennsylvania State University. The Graduate School. Graduate Program in Integrative Biosciences
The Pennsylvania State University The Graduate School Graduate Program in Integrative Biosciences A COMPREHENSIVE DOSE-RESPONSE STUDY OF THE EFFECTS OF PISTACHIOS ON CARDIOVASCULAR DISEASE RISK FACTORS:
More informationTHE MAKING OF A HEALTHY HEART: THE ROLE OF NUTRITION
THE MAKING OF A HEALTHY HEART: THE ROLE OF NUTRITION MONICA AGGARWAL, MD DIRECTOR OF NUTRITION, CARDIOVASCULAR DISEASES ASST PROFESSOR, DIVISION OF CARDIOLOGY UNIVERSITY OF FLORIDA PREVALENCE OF HEART
More informationSINCE THE PUBLICATION OF PIOneering
CLINICAL REVIEW CLINICIAN S CORNER Fish Intake, Contaminants, and Human Health Evaluating the Risks and the Benefits Dariush Mozaffarian, MD, DrPH Eric B. Rimm, ScD SINCE THE PUBLICATION OF PIOneering
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationEAT GOOD FATS TO MEET YOUR HEALTH GOALS!
EAT GOOD FATS TO MEET YOUR HEALTH GOALS! THE POWER OF GOOD FATS Did you know healthy fats provide a wealth of health benefits? At almost any age, replacing saturated fats* with polyunsaturated fats (omega-3,
More informationANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD
ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationFatty Acids: The Basics
Fatty Acids: The Basics Fatty Acids 101 Fatty acids are necessary nutrients found in our food. The problem is how much we eat of each: The historical ratio of omega-6s to omega- 3s may have been 1-to-1.
More informationn 3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article n 3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors The Risk and Prevention Study Collaborative Group* A BS TR AC
More informationIs Fat Where It s At? Gary E. Foresman, MD August 2012
Is Fat Where It s At? Gary E. Foresman, MD August 2012 Fats Through the Ages Fatty Acids Dietary Fats are Used to Build Every Cell in the Body Cell Membranes are Made From a Variety of Individual Fatty
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence
More informationProven and Proposed Cardiovascular Benefits of Soyfoods
Proven and Proposed Cardiovascular Benefits of Soyfoods Mark Messina, PhD, MS Soy Nutrition Institute Loma Linda University Nutrition Matters, Inc. markjohnmessina@gmail.com Alpro Foundation 20 years symposium
More informationCetoleic acid makes pelagic fish more healthy
Cetoleic acid makes pelagic fish more healthy WORKSHOP IN FISHMEAL AND FISH OIL, NOVEMBER 2018 Bente Ruyter Nofima Omega-3 fatty acids and health Eye Brain Cell membrane The marine omega-3 fatty acids
More information10/3/2016. SUPERSIZE YOUR KNOWLEDGE OF the CARDIAC DIET. What is a cardiac diet. If it tastes good, spit it out!!
SUPERSIZE YOUR KNOWLEDGE OF the CARDIAC DIET What is a cardiac diet If it tastes good, spit it out!! 2 1 Heart healthy diet includes: Limiting saturated fat Including unsaturated fats Including omega 3
More informationThe role of long-chain -3 fatty acids in the management
Clinical Investigation and Reports Fish and Long-Chain -3 Fatty Acid Intake and Risk of Coronary Heart Disease and Total Mortality in Diabetic Women Frank B. Hu, MD; Eunyoung Cho, ScD; Kathryn M. Rexrode,
More informationWeight Loss NOTES. [Diploma in Weight Loss]
Weight Loss NOTES [Diploma in Weight Loss] Fat s: The good, the bad and the ugly Fat s function in your body 1. Energy stores 2. Muscle fuel 3. Transportation 4. Cell membrane 5. Padding 6. Muscle fuel
More informationDo N3 Fatty Acid Supplements Effect Depressive Symptoms Post Cardiovascular Event in Men and Women Ages 40 and Older?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Do N3 Fatty Acid Supplements Effect Depressive
More informationNUTRITION Nutrition Information: Fats What is fat and are all fats created equal? The terms fatty acids and fats are often used interchangeably, but a fatty acid is the basic unit/building block of a fat
More informationGender: M Chart No: Fasting: Yes. Boston Heart HDL Map TM Test 1 ApoA-I (mg/dl) levels in HDL particles. α Range > <14 mg/dl. α-2 50.
Pro vider: Ordering Provider 123 Main Street Anytown, ST 12345 Account No: DOB: 00/00/1950 Framingham Risk Score: Patient Info: FAMILY HIST CVD Lipid, Lipoprotein and Apolipoprotein Tests Total Cholesterol
More informationShould I use statins?
I know the trials in heart failure but how do I manage my patient? Should I use statins? Aldo P Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Disclosures Aldo P Maggioni served as a member of
More informationCanakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Stable CAD (post MI) On Statin, ACE/ARB, BB, ASA Persistent Elevation of hscrp (> 2 mg/l) N = 10,061 39 Countries April 2011 - June 2017
More informationPRODUCT INFORMATION OMACOR
PRODUCT INFORMATION OMACOR NAME OF THE MEDICINE Non-proprietary Name Eicosapentaenoic acid (EPA) ethyl ester. Docosahexaenoic acid (DHA) ethyl ester. Chemical Structure Eicosapentaenoic acid (EPA) ethyl
More information